IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 713.55, up by 2.80 points or 0.39% from its previous closing of Rs. 710.75 on the BSE.

The scrip opened at Rs. 708.60 and has touched a high and low of Rs. 727.85 and Rs. 706.15 respectively. So far 5511 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 27-Apr-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022.

Last one week high and low of the scrip stood at Rs. 749.50 and Rs. 696.05 respectively. The current market cap of the company is Rs. 14025.76 crore.

The promoters holding in the company stood at 69.48%, while Institutions and Non-Institutions held 17.50% and 13.03% respectively.

Alembic Pharmaceuticals’ joint venture -- Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 U/g/0.1%, of Taro Pharmaceuticals U.S.A. Inc. Nystatin and Triamcinolone Acetonide Ointment is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.

Nystatin and Triamcinolone Acetonide Ointment has an estimated market size of $4 million for twelve months ending Dec 2021 according to IQVIA. Alembic has received year to date (YTD) 21 approvals (15 final approvals and 6 tentative approvals) and a cumulative total of 160 ANDA approvals (138 final approvals and 22 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.